PDS0202 is a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide durable protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. PDS0202 is given as a single dose by intramuscular injection and generates robust and durable protection against multiple strains of the flu in preclinical studies.
Influenza or flu is a contagious respiratory illness caused by highly variable and constantly evolving influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness and can result in death, particularly in the very young and elderly. According to the World Health Organization, influenza is estimated to result in about 3 to 5 million cases of severe illness, and about 290,000 to 650,000 respiratory deaths globally each year. There are several types of seasonal influenza viruses, which cause seasonal epidemics and emerging pandemics. A universal flu vaccine would provide robust, long-lasting protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu.
PDS0202 is currently in pre-clinical development.